Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.64 |
| ▸ | ANPEP | P15144 | 4/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PEPD | P12955 | 2/20 | 0.35 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049482 | 1.00 | MMP2 (0.64) | MMP2ANPEPBRD4MMP1MMP3 | |
| SCHEMBL17679758 | 1.00 | MMP2 (0.64) | MMP2ANPEPBRD4MMP1MMP3 | |
| SCHEMBL14367104 | 1.00 | MMP2 (0.64) | MMP2ANPEPBRD4MMP1MMP3 | |
| SCHEMBL15079077 | 1.00 | MMP2 (0.64) | MMP2ANPEPBRD4MMP1MMP3 | |
| Hydrochloric Acid SCHEMBL29414150 | 0.98 | MMP2 (0.62) | MMP2ANPEPBRD4MMP1MMP3 | |
| Hydrochloric Acid SCHEMBL30337475 | 0.98 | MMP2 (0.62) | MMP2ANPEPBRD4MMP1MMP3 | |
| Hydrochloric Acid SCHEMBL29129130 | 0.98 | MMP2 (0.62) | MMP2ANPEPBRD4MMP1MMP3 | |
| SCHEMBL13865290 | 0.83 | ANPEP (0.49) | MMP2ANPEPBRD4ALDH1A1GABRR1 | |
| SCHEMBL18536557 | 0.81 | ANPEP (0.51) | MMP2ANPEPALDH1A1CYP3A4MAPT | |
| SCHEMBL14288714 | 0.80 | MMP2 (0.42) | MMP2ANPEPALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794611-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | MMP2 4523/4885ANPEP 1097/4885BRD4 1551/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | MMP2 4523/4885ANPEP 1097/4885BRD4 1551/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | MMP2 4523/4885ANPEP 1097/4885BRD4 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.